Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Figures & data

Table 1 Patients’ characteristics pretreatment

Patient number	Age (years)	Fibrosis stage	Hemodialysis duration (months)	Treatment status	HCV RNA (IU/mL)	ALT (IU/mL)	Bilirubin (mg/dL)	Hemoglobin (g/dL)	Leukocytes (×10^9/L)	Platelets (×10^9/L)
1	25	F1	13	Naïve	120,000	96	0.35	15.1	7.2	219
2	37	F4	72	Treatment experienced	148,000	65	0.64	14.1	5.0	107
3	53	F1	84	Naïve	11,000,000	49	0.47	15.1	5.2	99
4	35	F1	25	Naïve	158,000	91	0.23	12.4	8.2	167
5	43	F1	24	Naïve	8,800,000	48	0.53	15.2	9.0	196
6	43	F4	26	Naïve	4,300,000	30	0.58	12.0	4.5	130
Mean	39		41		4,088,000	63	0.47	14.0	6.5	153
Median	40		26		2,229,000	57	0.53	14.6	6.2	149

Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus infection.